NEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended...
Y-mAbs Therapeutics Naxitamab-gqgk Receives Suppl Approval in the U.S
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
Y-mAbs Appoints Executive Mary Tagliaferri, M.D. to its Board of Directors
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial Results
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Q3 2023 DANYELZA® net product revenues of $20.0 million represents YoY growth of 59%U.S. FDA clearance of IND for CD38-SADA for relapsed or refractory non-Hodgkin LymphomaCash and cash equivalents of...
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results